Technetium uptake predicts remission and relapse in Grave's disease patients on antithyroid drugs for at least 1 year in South Indian subjects

Context: Most of the information on remission related factors in Grave's disease are derived from Western literature. It is likely that there may be additional prognostic factors and differences in the postdrug treatment course of Grave's disease in India. Aim: To study factors which predi...

Full description

Bibliographic Details
Main Authors: Neha Singhal, V P Praveen, Nisha Bhavani, Arun S Menon, Usha Menon, Nithya Abraham, Harish Kumar, R V JayKumar, Vasantha Nair, Shanmugha Sundaram, Padma Sundaram
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Indian Journal of Endocrinology and Metabolism
Subjects:
Online Access:http://www.ijem.in/article.asp?issn=2230-8210;year=2016;volume=20;issue=2;spage=157;epage=161;aulast=Singhal
id doaj-188d8752ad2a4e15ba190902138200e7
record_format Article
spelling doaj-188d8752ad2a4e15ba190902138200e72020-11-24T22:24:23ZengWolters Kluwer Medknow PublicationsIndian Journal of Endocrinology and Metabolism2230-82102230-95002016-01-0120215716110.4103/2230-8210.176360Technetium uptake predicts remission and relapse in Grave's disease patients on antithyroid drugs for at least 1 year in South Indian subjectsNeha SinghalV P PraveenNisha BhavaniArun S MenonUsha MenonNithya AbrahamHarish KumarR V JayKumarVasantha NairShanmugha SundaramPadma SundaramContext: Most of the information on remission related factors in Grave's disease are derived from Western literature. It is likely that there may be additional prognostic factors and differences in the postdrug treatment course of Grave's disease in India. Aim: To study factors which predict remission/relapse in Grave's disease patients from South India. Also to establish if technetium (Tc) uptake has a role in predicting remission. Subjects and Methods: Records of 174 patients with clinical, biochemical, and scintigraphic criteria consistent with Grave's disease, seen in our Institution between January 2006 and 2014 were analyzed. Patient factors, drug-related factors, Tc-99m uptake and other clinical factors were compared between the remission and nonremission groups. Statistical Analysis Used: Mann–Whitney U-test and Chi-square tests were used when appropriate to compare the groups. Results: Fifty-seven (32.7%) patients attained remission after at least 1 year of thionamide therapy. Of these, 11 (19.2%) patients relapsed within 1 year. Age, gender, goiter, and presence of extrathyroidal manifestations were not associated with remission. Higher values of Tc uptake were positively associated with remission (P- 0.02). Time to achievement of normal thyroid function and composite dose: Time scores were significantly associated with remission (P - 0.05 and P - 0.01, respectively). Patients with lower FT4 at presentation had a higher chance of remission (P - 0.01). The relapse rates were lower than previously reported in the literature. A higher Tc uptake was found to be significantly associated with relapse also (P - 0.009). Conclusion: The prognostic factors associated with remission in Graves's disease in this South Indian study are not the same as that reported in Western literature. Tc scintigraphy may have an additional role in identifying people who are likely to undergo remission and thus predict the outcome of Grave's disease.http://www.ijem.in/article.asp?issn=2230-8210;year=2016;volume=20;issue=2;spage=157;epage=161;aulast=SinghalGrave's diseaserelapseremissiontechnetium scintigraphy
collection DOAJ
language English
format Article
sources DOAJ
author Neha Singhal
V P Praveen
Nisha Bhavani
Arun S Menon
Usha Menon
Nithya Abraham
Harish Kumar
R V JayKumar
Vasantha Nair
Shanmugha Sundaram
Padma Sundaram
spellingShingle Neha Singhal
V P Praveen
Nisha Bhavani
Arun S Menon
Usha Menon
Nithya Abraham
Harish Kumar
R V JayKumar
Vasantha Nair
Shanmugha Sundaram
Padma Sundaram
Technetium uptake predicts remission and relapse in Grave's disease patients on antithyroid drugs for at least 1 year in South Indian subjects
Indian Journal of Endocrinology and Metabolism
Grave's disease
relapse
remission
technetium scintigraphy
author_facet Neha Singhal
V P Praveen
Nisha Bhavani
Arun S Menon
Usha Menon
Nithya Abraham
Harish Kumar
R V JayKumar
Vasantha Nair
Shanmugha Sundaram
Padma Sundaram
author_sort Neha Singhal
title Technetium uptake predicts remission and relapse in Grave's disease patients on antithyroid drugs for at least 1 year in South Indian subjects
title_short Technetium uptake predicts remission and relapse in Grave's disease patients on antithyroid drugs for at least 1 year in South Indian subjects
title_full Technetium uptake predicts remission and relapse in Grave's disease patients on antithyroid drugs for at least 1 year in South Indian subjects
title_fullStr Technetium uptake predicts remission and relapse in Grave's disease patients on antithyroid drugs for at least 1 year in South Indian subjects
title_full_unstemmed Technetium uptake predicts remission and relapse in Grave's disease patients on antithyroid drugs for at least 1 year in South Indian subjects
title_sort technetium uptake predicts remission and relapse in grave's disease patients on antithyroid drugs for at least 1 year in south indian subjects
publisher Wolters Kluwer Medknow Publications
series Indian Journal of Endocrinology and Metabolism
issn 2230-8210
2230-9500
publishDate 2016-01-01
description Context: Most of the information on remission related factors in Grave's disease are derived from Western literature. It is likely that there may be additional prognostic factors and differences in the postdrug treatment course of Grave's disease in India. Aim: To study factors which predict remission/relapse in Grave's disease patients from South India. Also to establish if technetium (Tc) uptake has a role in predicting remission. Subjects and Methods: Records of 174 patients with clinical, biochemical, and scintigraphic criteria consistent with Grave's disease, seen in our Institution between January 2006 and 2014 were analyzed. Patient factors, drug-related factors, Tc-99m uptake and other clinical factors were compared between the remission and nonremission groups. Statistical Analysis Used: Mann–Whitney U-test and Chi-square tests were used when appropriate to compare the groups. Results: Fifty-seven (32.7%) patients attained remission after at least 1 year of thionamide therapy. Of these, 11 (19.2%) patients relapsed within 1 year. Age, gender, goiter, and presence of extrathyroidal manifestations were not associated with remission. Higher values of Tc uptake were positively associated with remission (P- 0.02). Time to achievement of normal thyroid function and composite dose: Time scores were significantly associated with remission (P - 0.05 and P - 0.01, respectively). Patients with lower FT4 at presentation had a higher chance of remission (P - 0.01). The relapse rates were lower than previously reported in the literature. A higher Tc uptake was found to be significantly associated with relapse also (P - 0.009). Conclusion: The prognostic factors associated with remission in Graves's disease in this South Indian study are not the same as that reported in Western literature. Tc scintigraphy may have an additional role in identifying people who are likely to undergo remission and thus predict the outcome of Grave's disease.
topic Grave's disease
relapse
remission
technetium scintigraphy
url http://www.ijem.in/article.asp?issn=2230-8210;year=2016;volume=20;issue=2;spage=157;epage=161;aulast=Singhal
work_keys_str_mv AT nehasinghal technetiumuptakepredictsremissionandrelapseingravesdiseasepatientsonantithyroiddrugsforatleast1yearinsouthindiansubjects
AT vppraveen technetiumuptakepredictsremissionandrelapseingravesdiseasepatientsonantithyroiddrugsforatleast1yearinsouthindiansubjects
AT nishabhavani technetiumuptakepredictsremissionandrelapseingravesdiseasepatientsonantithyroiddrugsforatleast1yearinsouthindiansubjects
AT arunsmenon technetiumuptakepredictsremissionandrelapseingravesdiseasepatientsonantithyroiddrugsforatleast1yearinsouthindiansubjects
AT ushamenon technetiumuptakepredictsremissionandrelapseingravesdiseasepatientsonantithyroiddrugsforatleast1yearinsouthindiansubjects
AT nithyaabraham technetiumuptakepredictsremissionandrelapseingravesdiseasepatientsonantithyroiddrugsforatleast1yearinsouthindiansubjects
AT harishkumar technetiumuptakepredictsremissionandrelapseingravesdiseasepatientsonantithyroiddrugsforatleast1yearinsouthindiansubjects
AT rvjaykumar technetiumuptakepredictsremissionandrelapseingravesdiseasepatientsonantithyroiddrugsforatleast1yearinsouthindiansubjects
AT vasanthanair technetiumuptakepredictsremissionandrelapseingravesdiseasepatientsonantithyroiddrugsforatleast1yearinsouthindiansubjects
AT shanmughasundaram technetiumuptakepredictsremissionandrelapseingravesdiseasepatientsonantithyroiddrugsforatleast1yearinsouthindiansubjects
AT padmasundaram technetiumuptakepredictsremissionandrelapseingravesdiseasepatientsonantithyroiddrugsforatleast1yearinsouthindiansubjects
_version_ 1725761558377660416